NASDAQ · MRNA
Moderna, Inc.
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
Loading market information…
NASDAQ · VIR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vir Biotechnology, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.74. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vir Biotechnology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$0.88-6.02% vs estimate | $1.79M-79.12% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.76+10.59% vs estimate | $12.37M+52.01% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | -$1.56-62.5% vs estimate | $2.38M-74.59% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $23.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
$89.13+$1.14 (+1.3%)
BioNTech SE’s quoted price sits in the lower half of its reported 52-week range, 28.12% below the high.
$8.52+$0.15 (+1.79%)
BioCryst Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
$10.47+$0.15 (+1.45%)
Novavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.81% below the high.
$4.28-$0.04 (-0.93%)
Arbutus Biopharma Corp’s quoted price sits in the lower half of its reported 52-week range, 21.47% below the high.
$5.71-$0.03 (-0.52%)
Valneva SE’s quoted price sits in the lower half of its reported 52-week range, 53.12% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
